|
Variable
|
Median
|
Disease-free survival (months)
|
P value
|
|---|
|
95% CI
|
|---|
|
Gender
| | |
0.029
|
|
Male
|
29.2
|
23.1–35.3
| |
|
Female
|
42.9
|
22.4–63.3
| |
|
Age
| | |
0.608
|
|
<65 years
|
34.2
|
26.6–41.9
| |
|
≥65 years
|
27.2
|
20.5–33.9
| |
|
Smoking status
| | |
0.064
|
|
Non-smoker
|
43.7
|
20.9–66.4
| |
|
Smoker
|
28.7
|
22.6–34.8
| |
|
Tumour location
| | |
0.379
|
|
Upper
|
27.1
|
20.7–33.5
| |
|
Middle
|
39.2
|
31.1–47.2
| |
|
Lower
|
27.2
|
20.9–33.5
| |
|
Tumour length
| | |
0.003
|
|
≤4.0 cm
|
42.9
|
34.4–51.3
| |
|
>4.0 cm
|
27.4
|
23.0–31.8
| |
|
Surgical approach
| | |
0.734
|
|
Right incision
|
27.2
|
19.3–35.0
| |
|
Left incision
|
35.3
|
27.7–42.8
| |
|
Differentiation
| | |
0.763
|
|
G1
|
30.0
|
19.7–40.3
| |
|
G2
|
32.8
|
22.0–43.6
| |
|
G3
|
35.5
|
21.0–49.8
| |
|
p T stage
| | |
<0.001
|
|
T1+T2
|
56.3
|
28.3–84.3
| |
|
T3+T4
|
27.1
|
22.6–31.5
| |
|
p N stage
| | |
<0.001
|
|
N0
|
68.5
|
45.4–91.6
| |
|
N1+N2+N3
|
19.7
|
13.9–25.5
| |
|
Adjuvant therapy
| | |
0.570
|
|
With
|
38.8
|
29.4–48.2
| |
|
Without
|
27.8
|
22.4–33.1
| |
|
p TNM stage
| | |
<0.001
|
|
I stage
|
71.4
|
43.9–98.8
| |
|
II stage
|
56.7
|
31.1–82.3
| |
|
III stage
|
21.6
|
15.7–27.5
| |
|
IV stage
|
10.8
|
4.9–16.6
| |
|
Vascular invasion
| | |
0.001
|
|
Presence
|
21.0
|
15.5–26.5
| |
|
No
|
41.8
|
32.1–51.6
| |
|
Lymphatic invasion
| | |
<0.001
|
|
Presence
|
18.6
|
11.1–26.1
| |
|
No
|
41.0
|
31.8–50.2
| |
